Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth
- Cancer Discov. 2024 Jul 3. doi: 10.1158/2159-8290.CD-24-0100.
- 1. University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
- 2. University of Michigan Medical School, Ann Arbor, MI, United States.
- 3. University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
- 4. University of Michigan Medical Schooligan, United States.
- 5. University of Michigan-Ann Arbor, Ann Arbor, United States.
- 6. University of Michigan-Ann Arbor, United States.
Pancreatic Cancer is characterized by an extensive fibroinflammatory microenvironment. During carcinogenesis, normal stromal cells are converted to cytokine-high Cancer associated fibroblasts (CAFs). The mechanisms underlying this conversion, including regulation and function of fibroblast-derived cytokines, are poorly understood. Thus, efforts to target CAFs therapeutically have so far failed. Here, we show that signals from epithelial cells expressing oncogenic KRAS -a hallmark pancreatic Cancer mutation- activate fibroblast autocrine signaling, which drives expression of the cytokine interleukin-33 (IL-33). Stromal IL-33 expression remains high and dependent on epithelial KRAS throughout carcinogenesis; in turn, environmental stress induces IL-33 secretion. Using compartment-specific IL-33 knockout mice, we observed that lack of stromal IL-33 leads to profound reprogramming of multiple components of the pancreatic tumor microenvironment, including CAFs, myeloid cells and lymphocytes. Notably, loss of stromal IL-33 leads to an increase in CD8+ T cell infiltration and activation, and, ultimately, reduced tumor growth.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
target: TGF-β ReceptorResearch Areas: Cancer